263 related articles for article (PubMed ID: 22644035)
41. HIV-1
Kapaata A; Balinda SN; Xu R; Salazar MG; Herard K; Brooks K; Laban K; Hare J; Dilernia D; Kamali A; Ruzagira E; Mukasa F; Gilmour J; Salazar-Gonzalez JF; Yue L; Cotten M; Hunter E; Kaleebu P
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498793
[TBL] [Abstract][Full Text] [Related]
42. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
43. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
44. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
45. Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study.
Palanisamy N; Osman N; Ohnona F; Xu HT; Brenner B; Mesplède T; Wainberg MA
AIDS Res Ther; 2017 Jan; 14(1):2. PubMed ID: 28086981
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
47. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
[TBL] [Abstract][Full Text] [Related]
48. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors.
Codoñer FM; Peña R; Blanch-Lombarte O; Jimenez-Moyano E; Pino M; Vollbrecht T; Clotet B; Martinez-Picado J; Draenert R; Prado JG
Sci Rep; 2017 Jun; 7(1):3717. PubMed ID: 28623276
[TBL] [Abstract][Full Text] [Related]
49. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
[TBL] [Abstract][Full Text] [Related]
50. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
Deshmukh L; Louis JM; Ghirlando R; Clore GM
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12456-12461. PubMed ID: 27791180
[TBL] [Abstract][Full Text] [Related]
51. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
[TBL] [Abstract][Full Text] [Related]
52. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
[TBL] [Abstract][Full Text] [Related]
54. Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease.
Flynn WF; Chang MW; Tan Z; Oliveira G; Yuan J; Okulicz JF; Torbett BE; Levy RM
PLoS Comput Biol; 2015 Apr; 11(4):e1004249. PubMed ID: 25894830
[TBL] [Abstract][Full Text] [Related]
55. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
[TBL] [Abstract][Full Text] [Related]
56. Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.
Kozísek M; Sasková KG; Rezácová P; Brynda J; van Maarseveen NM; De Jong D; Boucher CA; Kagan RM; Nijhuis M; Konvalinka J
J Virol; 2008 Jun; 82(12):5869-78. PubMed ID: 18400858
[TBL] [Abstract][Full Text] [Related]
57. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
[TBL] [Abstract][Full Text] [Related]
58. GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
Grantz Šašková K; Kozíšek M; Stray K; de Jong D; Rezáová P; Brynda J; van Maarseveen NM; Nijhuis M; Cihlár T; Konvalinka J
J Virol; 2014 Mar; 88(6):3586-90. PubMed ID: 24371077
[TBL] [Abstract][Full Text] [Related]
59. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
60. Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Marie V; Gordon M
J Biomol Struct Dyn; 2022; 40(21):10852-10861. PubMed ID: 34253143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
